autoimmune diseases

News

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

News

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

News

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.